Keyword Search

Date Title
05/29/24 Aadi Bioscience to Participate in the Jefferies Healthcare Conference
05/23/24 Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting
05/08/24 Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update
05/01/24 Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update
04/09/24 Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting
03/17/24 Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)
03/13/24 Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update
03/06/24 Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update
03/05/24 Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
03/01/24 Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa
02/26/24 Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference
01/26/24 Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium
01/19/24 Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium